Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 15/20 | 0.56 |
| ▸ | CTSD | P07339 | 1/20 | 0.52 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29470277 | 0.98 | BACE1 (0.55) | BACE1CTSDOPRM1OPRD1OPRK1 | |
| SCHEMBL30193015 | 0.97 | BACE1 (0.53) | BACE1CTSDNAALAD2OPRM1OPRD1 | |
| SCHEMBL29590401 | 0.94 | BACE1 (0.51) | BACE1CTSDNAALAD2OPRM1OPRD1 | |
| SCHEMBL29695521 | 0.93 | BACE1 (0.52) | BACE1CTSDNAALAD2OPRM1OPRD1 | |
| SCHEMBL31031528 | 0.91 | NAALAD2 (0.55) | BACE1CTSDNAALAD2OPRM1OPRD1 | |
| SCHEMBL31031476 | 0.91 | BACE1 (0.54) | BACE1CTSDNAALAD2OPRM1OPRD1 | |
| SCHEMBL29590749 | 0.91 | OPRD1 (0.48) | BACE1OPRM1OPRD1OPRK1 | |
| SCHEMBL29590787 | 0.90 | BACE1 (0.60) | BACE1CTSDNAALAD2BACE2 | |
| SCHEMBL31094953 | 0.89 | NAALAD2 (0.60) | BACE1CTSDNAALAD2BACE2 | |
| SCHEMBL29630505 | 0.89 | BACE1 (0.58) | BACE1CTSDNAALAD2BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109748-A1 | MODULATION OF DENDRITIC CELL LINEAGES | ORIONIS BIOSCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12583898-B2 | Therapeutic interferon alpha 1 proteins | ORIONIS BIOSCIENCES, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12544426-B2 | Combination therapy with CD13-targeted chimeric proteins or chimeric protein complexes | ORIONIS BIOSCIENCES, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12473338-B2 | Targeted engineered interferon and uses thereof | ORIONIS BIOSCIENCES, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12410225-B2 | Modulation of dendritic cell lineages | Orionis Biosciences, Inc (US) | 2025-09-09 | — | — | US | disclosed |
| EP-3576765-B1 | TARGETED ENGINEERED INTERFERON AND USES THEREOF | ORIONIS BIOSCIENCES INC (US) | 2025-07-16 | — | — | EP | disclosed |
| CN-113767115-B | Therapeutic interferon alpha 1 proteins | 奥里尼斯生物科学股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20240368277-A1 | SIRP1a TARGETED CHIMERIC PROTEINS AND USES THEREOF | Orionis Biosciences BV (BE) | 2024-11-07 | — | — | US | disclosed |
| US-20240358826-A1 | INTERLEUKIN-1 ALPHA CHIMERIC PROTEIN | ORIONIS BIOSCIENCES, INC. | 2024-10-31 | — | — | US | disclosed |
| US-12084497-B2 | SIRP1α targeted chimeric proteins and uses thereof | ORIONIS BIOSCIENCES, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-11440943-B2 | Therapeutic interferon alpha 1 proteins | ORIONIS BIOSCIENCES, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-20220281992-A1 | TARGETED CHIMERIC PROTEINS AND USES THEREOF | Orionis Biosciences BV (BE) | 2022-09-08 | — | — | US | disclosed |
| US-20220249609-A1 | COMBINATION THERAPY WITH CD13-TARGETED CHIMERIC PROTEINS OR CHIMERIC PROTEIN COMPLEXES | UNIVERSITEIT GENT (BE) | 2022-08-11 | — | — | US | disclosed |
| EP-4034565-A1 | PD-L1 TARGETED CHIMERIC PROTEINS AND USES THEREOF | Orionis Biosciences, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-4034146-A1 | CONJUGATED CHIMERIC PROTEINS | Orionis Biosciences, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| CN-114761430-A | Chimeric protein targeting PD-L1 and application thereof | 奥里尼斯生物科学股份有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-11384154-B2 | Targeted chimeric proteins and uses thereof | Orionis Biosciences BV (BE) | 2022-07-12 | — | — | US | disclosed |
| US-20220119519-A1 | SIRP1A TARGETED CHIMERIC PROTEINS AND USES THEREOF | Orionis Biosciences BV (BE) | 2022-04-21 | — | — | US | disclosed |
| US-20220119472-A1 | MODULATION OF DENDRITIC CELL LINEAGES | Orionis Biosciences BV (BE) | 2022-04-21 | — | — | US | disclosed |
| EP-3946410-A1 | THERAPEUTIC INTERFERON ALPHA 1 PROTEINS | Orionis Biosciences, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440943-B2 | Therapeutic interferon alpha 1 proteins | IFNAR1, IFNG, FCGR1A | BACE1 1638/4885CTSD 1004/4885NAALAD2 1713/4885 |
| US-12410225-B2 | Modulation of dendritic cell lineages | CLEC4M, CD40LG, HAVCR2 | BACE1 3146/4885CTSD 902/4885NAALAD2 1328/4885 |
| US-20240368277-A1 | SIRP1a TARGETED CHIMERIC PROTEINS AND USES THEREOF | CD47, SIRT1, CHP1 | BACE1 2092/4885CTSD 3086/4885NAALAD2 3230/4885 |
| US-20220281992-A1 | TARGETED CHIMERIC PROTEINS AND USES THEREOF | CD47, CHP1, PHLPP1 | BACE1 1623/4885CTSD 2823/4885NAALAD2 2972/4885 |
| US-12583898-B2 | Therapeutic interferon alpha 1 proteins | FCGR3B, FCGR2A, IFNAR1 | BACE1 694/4885CTSD 229/4885NAALAD2 2475/4885 |
| US-20260109748-A1 | MODULATION OF DENDRITIC CELL LINEAGES | FCGR3B, VSIG8, TNFRSF9 | BACE1 1289/4885CTSD 405/4885NAALAD2 1334/4885 |
| US-12544426-B2 | Combination therapy with CD13-targeted chimeric proteins or chimeric protein complexes | TNFRSF9, CD40, TNFSF11 | BACE1 3634/4885CTSD 674/4885NAALAD2 4025/4885 |
| US-20220119519-A1 | SIRP1A TARGETED CHIMERIC PROTEINS AND USES THEREOF | CD47, SIRT1, CHP1 | BACE1 2092/4885CTSD 3086/4885NAALAD2 3230/4885 |
| US-20240358826-A1 | INTERLEUKIN-1 ALPHA CHIMERIC PROTEIN | IL1A, IL1B, IL1R1 | BACE1 562/4885CTSD 2133/4885NAALAD2 2370/4885 |
| US-12084497-B2 | SIRP1α targeted chimeric proteins and uses thereof | CD47, SIRT1, CHP1 | BACE1 1816/4885CTSD 2982/4885NAALAD2 3114/4885 |
| US-20220119472-A1 | MODULATION OF DENDRITIC CELL LINEAGES | CLEC4M, CD40LG, HAVCR2 | BACE1 3146/4885CTSD 902/4885NAALAD2 1328/4885 |
| US-12473338-B2 | Targeted engineered interferon and uses thereof | IFNG, IFNAR1, STING1 | BACE1 2148/4885CTSD 569/4885NAALAD2 1785/4885 |
| US-11384154-B2 | Targeted chimeric proteins and uses thereof | CD47, CHP1, PHLPP1 | BACE1 1623/4885CTSD 2823/4885NAALAD2 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.